Search results
Results from the WOW.Com Content Network
In 2008 a new resolution from ANVISA (Control Agency for Sanitary Vigilance), Resolution 96 from December 17 was released, with focus on medication advertisements. It allows direct-to-consumer advertising of non-prescription medication, with restrictions on the type of drug and words and images that can be used, among other things. [15]
Pharmaceutical marketing is a branch of marketing science and practice focused on the ... Only two countries as of 2008 allow direct to consumer advertising ...
One year later, spending on television drug ads had more than doubled, from $310 million to $664 million. A major early beneficiary was a new generation of antihistamines that did not make people drowsy. Thanks to the advertising push, first Claritin, then Zyrtec and Allegra became some of the most frequently prescribed medications in America.
The idea is that countries with non-SRA drug authorities can use accelerated process to facilitate approval (registration or marketing authorization) of medicines, including vaccines and biologics, which have already been approved by SRAs. [1] As of 2022, the national regulatory authorities of 36 countries are considered SRAs: [2]
Advertising is all about presenting a product in the most flattering light possible. Still, there are limits to what marketers can and cannot say, particularly when it comes to hawking items that ...
This directly led to Congress passing the Sherley Amendment which established a clearer definition of 'drug marketing requirements'. [7] More catalysts for advances in drug regulation in the US were certain catastrophes that served as calls to the US government to step in and impose regulations that would prevent repeats of those instances.
Those ever-present TV drug ads showing patients hiking, biking or enjoying a day at the beach could soon have a different look: New rules require drugmakers to be clearer and more direct when ...
A centralised marketing authorisation, issued by the European Commission, allows the holder to market a medicinal product throughout the European Economic Area (EEA), which comprises the EU Member States, Iceland, Norway and Liechtenstein. [2] In the United States, the equivalent process is called New Drug Application.